miRNA-23a has been shown to inhibit the effectiveness of lung cancer drugs such as EGFR-targeted tyrosine kinase inhibitors by suppressing their ability to phosphorylate PI3K and AKT in lung CSCs, thereby preventing the induction of apoptosis in the cells (Han et al., 2017). Here, EGFR is linked to lung cancer.